+

CN115380026A - 蛋白降解调节剂与其使用方法 - Google Patents

蛋白降解调节剂与其使用方法 Download PDF

Info

Publication number
CN115380026A
CN115380026A CN202180024213.6A CN202180024213A CN115380026A CN 115380026 A CN115380026 A CN 115380026A CN 202180024213 A CN202180024213 A CN 202180024213A CN 115380026 A CN115380026 A CN 115380026A
Authority
CN
China
Prior art keywords
independently selected
reaction
reaction mixture
ethyl acetate
room temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180024213.6A
Other languages
English (en)
Other versions
CN115380026B (zh
Inventor
雷茂义
彭蕾
罗云富
徐雨
栗俊苗
邓新媛
康子圣
戈伟智
张国利
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN115380026A publication Critical patent/CN115380026A/zh
Application granted granted Critical
Publication of CN115380026B publication Critical patent/CN115380026B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

一类蛋白降解靶向嵌合体(PROTAC)，及其在制备治疗相关疾病的药物中的应用。具体公开了式(I)所示化合物及其药学上可接受的盐。PTM‑L‑ULM(I)。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN202180024213.6A 2020-03-17 2021-03-17 蛋白降解调节剂与其使用方法 Active CN115380026B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN202010187846 2020-03-17
CN2020101878466 2020-03-17
CN2020114003674 2020-12-01
CN202011400367 2020-12-01
CN2020115835841 2020-12-28
CN202011583584 2020-12-28
CN202110182231 2021-02-09
CN2021101822319 2021-02-09
PCT/CN2021/081375 WO2021185291A1 (zh) 2020-03-17 2021-03-17 蛋白降解调节剂与其使用方法

Publications (2)

Publication Number Publication Date
CN115380026A true CN115380026A (zh) 2022-11-22
CN115380026B CN115380026B (zh) 2023-11-07

Family

ID=77770306

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180024213.6A Active CN115380026B (zh) 2020-03-17 2021-03-17 蛋白降解调节剂与其使用方法

Country Status (5)

Country Link
US (1) US20230158152A1 (zh)
EP (1) EP4122925A4 (zh)
JP (1) JP2023517393A (zh)
CN (1) CN115380026B (zh)
WO (1) WO2021185291A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117327077A (zh) * 2023-10-07 2024-01-02 中国药科大学 苯胺基嘧啶并杂环类化合物及其制备方法、药物组合物和应用

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240424110A1 (en) * 2020-03-19 2024-12-26 Kymera Therapeutics, Inc. Mdm2 degraders and uses thereof
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
US20240190851A1 (en) * 2021-03-17 2024-06-13 Medshine Discovery Inc. Furan fused ring-substituted glutarimide compound
PH12023500023A1 (en) 2021-05-07 2024-03-11 Kymera Therapeutics Inc Cdk2 degraders and uses thereof
WO2022262782A1 (zh) * 2021-06-17 2022-12-22 南京明德新药研发有限公司 戊二酰亚胺取代的异噁唑稠环化合物及其应用
WO2023001028A1 (zh) * 2021-07-19 2023-01-26 南京明德新药研发有限公司 杂芳-3-哌啶二酮类化合物及其应用
JP2024536872A (ja) * 2021-09-26 2024-10-08 メッドシャイン ディスカバリー インコーポレイテッド ２，６－ピペリジンジオン系化合物とその使用
JP2024542178A (ja) * 2021-11-18 2024-11-13 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 縮合イミド誘導体
CN118451069A (zh) * 2021-12-31 2024-08-06 正大天晴药业集团股份有限公司 含有杂环的化合物
CN116535423B (zh) * 2022-01-26 2025-06-06 武汉誉祥医药科技有限公司 抑制/诱导降解egfr激酶的化合物及其药物组合物和应用
CN114573534B (zh) * 2022-03-30 2025-01-24 八叶草健康产业研究院(厦门)有限公司 一种5-溴苯并呋喃酮的制备方法
AR129422A1 (es) * 2022-05-25 2024-08-21 Univ Leuven Kath Nuevos derivados para tratar trastornos mediados por trpm3
WO2024034593A1 (ja) * 2022-08-09 2024-02-15 アステラス製薬株式会社 Ｇ１２ｖ変異ｋｒａｓタンパクの分解を誘導するための複素環化合物
JP2025528193A (ja) * 2022-08-19 2025-08-26 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド シクロヘキシル基を含む化合物
EP4588916A1 (en) * 2022-09-14 2025-07-23 Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. Crystal form of naphthofuran-substituted glutarimide compound, and preparation method therefor and use thereof
CN118005636A (zh) * 2022-11-08 2024-05-10 杭州格博生物医药有限公司 Wee1蛋白激酶降解剂及其用途
WO2024146502A1 (en) * 2023-01-03 2024-07-11 Beijing Neox Biotech Limited Wee1 degrading compounds
EP4428133A1 (en) * 2023-03-07 2024-09-11 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bifunctional protein targeting chimeras (protacs) comprising arylidene-indolinone scaffold as dcaf11 ligand and use thereof
WO2024199135A1 (zh) * 2023-03-24 2024-10-03 漳州片仔癀药业股份有限公司 2,6-哌啶二酮类化合物盐型和晶型的制备方法及其应用
WO2024199147A1 (zh) * 2023-03-24 2024-10-03 漳州片仔癀药业股份有限公司 2,6-哌啶二酮类化合物的晶型、制备方法及其应用
CN120623148A (zh) * 2024-03-11 2025-09-12 北京深势科技有限公司 一种c-Myc降解剂及其制备方法和用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019060742A1 (en) * 2017-09-22 2019-03-28 Kymera Therapeutics, Inc AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
CN109641874A (zh) * 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN110612294A (zh) * 2017-01-31 2019-12-24 阿尔维纳斯运营股份有限公司 人小脑蛋白配体和包含其的双官能化合物
WO2020048548A1 (zh) * 2018-09-07 2020-03-12 正大天晴药业集团股份有限公司 一种作用于crbn蛋白的三并环类化合物
WO2020048546A1 (zh) * 2018-09-07 2020-03-12 南京明德新药研发有限公司 三环取代哌啶二酮类化合物
WO2020048547A1 (zh) * 2018-09-07 2020-03-12 南京明德新药研发有限公司 三环并呋喃取代哌啶二酮类化合物
CN114401962A (zh) * 2019-09-12 2022-04-26 南京明德新药研发有限公司 作为crbn蛋白调节剂的双并环类化合物
CN114761400A (zh) * 2019-09-12 2022-07-15 南京明德新药研发有限公司 一种可降解蛋白的并环类化合物及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
JP2002515431A (ja) * 1998-05-15 2002-05-28 アメリカン・ホーム・プロダクツ・コーポレイション エストロゲンと組み合わせる２−フェニル−１−［４−（２−アミノエトキシ）ベンジルオキシ］インドール
ATE529406T1 (de) * 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
DOP2003000613A (es) * 2002-03-13 2003-09-30 Array Biopharma Inc Derivados de bencimidazol n3 alquilado como inhibidores de mek (n3 alkylated benzimidazole derivatives as mek inhibitors)
ES2444433T3 (es) * 2008-11-14 2014-02-25 Concert Pharmaceuticals, Inc. Derivados de dioxopiperidinil-ftalimida sustituidos
EP2430016B1 (en) * 2009-05-13 2020-04-01 University Of Virginia Patent Foundation Inhibitors of inv(16) leukemia
CN103159680A (zh) * 2011-12-14 2013-06-19 爱美尼迪药物有限公司 咪唑二酮类化合物及其用途
EP2892537A1 (en) * 2012-09-10 2015-07-15 Celgene Corporation Methods for the treatment of locally advanced breast cancer
KR20210132233A (ko) * 2014-04-14 2021-11-03 아비나스 오퍼레이션스, 인코포레이티드 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
WO2016105518A1 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017075629A2 (en) * 2015-11-01 2017-05-04 The Regents Of The University Of Colorado, A Body Corporate Wee 1 kinase inhibitors and methods of making and using the same
JP2018531983A (ja) * 2015-11-02 2018-11-01 イエール ユニバーシティ タンパク質分解誘導キメラ化合物ならびにその調製方法および使用方法
US11192898B2 (en) * 2016-04-06 2021-12-07 The Regents Of The University Of Michigan MDM2 protein degraders
WO2017185031A1 (en) * 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
EP3351544A1 (en) * 2017-01-12 2018-07-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Benzene disulfonamide for the treatment of cancer
US11358948B2 (en) * 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
WO2019113071A1 (en) * 2017-12-05 2019-06-13 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating alk-mediated cancer
IL315310A (en) * 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
US11220515B2 (en) * 2018-01-26 2022-01-11 Yale University Imide-based modulators of proteolysis and associated methods of use
WO2019196812A1 (zh) * 2018-04-09 2019-10-17 上海科技大学 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用
JP2021521192A (ja) * 2018-04-13 2021-08-26 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． セレブロンリガンドおよび同リガンドを含む二機能性化合物
US20220348556A1 (en) * 2018-07-06 2022-11-03 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020010210A1 (en) * 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Mertk degraders and uses thereof
JP7692924B2 (ja) * 2020-02-26 2025-06-16 クルゲン（シャンハイ），インク． トロポミオシン受容体キナーゼ（ｔｒｋ）分解化合物とその使用方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109641874A (zh) * 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN110612294A (zh) * 2017-01-31 2019-12-24 阿尔维纳斯运营股份有限公司 人小脑蛋白配体和包含其的双官能化合物
WO2019060742A1 (en) * 2017-09-22 2019-03-28 Kymera Therapeutics, Inc AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
WO2020048548A1 (zh) * 2018-09-07 2020-03-12 正大天晴药业集团股份有限公司 一种作用于crbn蛋白的三并环类化合物
WO2020048546A1 (zh) * 2018-09-07 2020-03-12 南京明德新药研发有限公司 三环取代哌啶二酮类化合物
WO2020048547A1 (zh) * 2018-09-07 2020-03-12 南京明德新药研发有限公司 三环并呋喃取代哌啶二酮类化合物
CN114401962A (zh) * 2019-09-12 2022-04-26 南京明德新药研发有限公司 作为crbn蛋白调节剂的双并环类化合物
CN114761400A (zh) * 2019-09-12 2022-07-15 南京明德新药研发有限公司 一种可降解蛋白的并环类化合物及其应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117327077A (zh) * 2023-10-07 2024-01-02 中国药科大学 苯胺基嘧啶并杂环类化合物及其制备方法、药物组合物和应用

Also Published As

Publication number Publication date
CN115380026B (zh) 2023-11-07
WO2021185291A1 (zh) 2021-09-23
EP4122925A4 (en) 2024-04-17
US20230158152A1 (en) 2023-05-25
JP2023517393A (ja) 2023-04-25
EP4122925A1 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
CN115380026A (zh) 蛋白降解调节剂与其使用方法
CN113087700B (zh) 螺环四氢喹唑啉
TWI855062B (zh) Bcl-2抑制劑
CN108137607B (zh) 适用于治疗与ntrk相关的病症的化合物和组合物
JP6670756B2 (ja) ブルトン型チロシンキナーゼ（ｂｔｋ）インヒビターとしての多フルオロ置換化合物
CN115192577A (zh) Kras突变蛋白抑制剂
CN113286794A (zh) Kras突变蛋白抑制剂
CN116867769A (zh) 取代的哒嗪苯酚类衍生物
CN112689627B (zh) 三环取代哌啶二酮类化合物
CN112654619B (zh) 三环并呋喃取代哌啶二酮类化合物
TW201920115A (zh) 化合物、組合物及方法
TW201823249A (zh) Ｍｅｎｉｎ－ｍｌｌ相互作用之稠合二環抑制劑
CN104812748B (zh) 二氢吡唑gpr40调节剂
CN114072407A (zh) 靶向prmt5的化合物
CN107922417A (zh) 蝶啶酮衍生物作为egfr抑制剂的应用
CN118201930A (zh) Wee1蛋白激酶降解剂及其用途
WO2022194269A1 (zh) 新型egfr降解剂
KR20250129683A (ko) Pan-kras 단백질 분해제를 표적하는 화합물 및 이의 용도
KR20240019071A (ko) N2-페닐피리미딘-2,4-디아민 화합물, 및 그 제조 방법 및 사용 방법
WO2022247757A1 (zh) 氟取代的嘧啶并吡啶类化合物及其应用
WO2023078413A1 (zh) Fgfr2抑制剂、及其制备方法和医药用途
CN111344282A (zh) 喹唑啉酮类化合物及其应用
WO2021115335A1 (zh) 作为周期蛋白依赖性激酶9抑制剂的化合物及其应用
AU2005213538A1 (en) Piperidinylcarbonyl-pyrrolidines and their use as melanocortin agonists
WO2023208127A1 (zh) 杂芳基取代的双环化合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40081349

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载